Skip to main content
Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 61.22
Day High 61.54
Open:61.46
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

FDA approves Ozempic® for cardiovascular risk reduction in adults with type 2 diabetes and known heart disease, updates Rybelsus® label
- PR Newswire - Thu Jan 16, 4:56PM CST
PR Newswire - CMTX
Thu Jan 16, 4:56PM CST
Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Ozempic® (semaglutide) injection 0.5 mg or 1 mg to reduce the risk of major adverse cardiovascular events (MACE) such as heart attack, stroke, or death in adults with type 2 diabetes and known heart disease.1 Additional details were added to the Rybelsus® (semaglutide) tablets 7 mg or 14 mg Prescribing Information about the primary analysis for PIONEER 6.
Ozempic(R) approved in the US for CV risk reduction in people with type 2 diabetes and established CVD
- Globe Newswire - Thu Jan 16, 4:38PM CST
Globe Newswire - CMTX
Thu Jan 16, 4:38PM CST
Rybelsus(R) label updated with additional information from the PIONEER 6 CV outcomes trial
Just - Evotec Biologics Announces Product Development And Manufacturing Agreement With Oncoresponse
- ACCESSWIRE - Thu Jan 16, 12:41AM CST
ACCESSWIRE - CMTX
Thu Jan 16, 12:41AM CST
JUST - EVOTEC BIOLOGICS WILL APPLY ITS FULLY INTEGRATED TECHNOLOGY PLATFORM IN ORDER TO ACCELERATE ONCORESPONSE'S LEAD PRODUCT CANDIDATE THROUGH DEVELOPMENT AND INTO THE CLINIC
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 56.56 +8.40% increase
on 01/07/20
Period Open:58.17
Price movement based on the high, low and last over the given period.
62.69 -2.20% decrease
on 01/15/20
+3.14 (+5.40%) increase
since 12/17/19
3-Month 52.17 +17.52% increase
on 10/18/19
Period Open:52.68
Price movement based on the high, low and last over the given period.
62.69 -2.20% decrease
on 01/15/20
+8.63 (+16.38%) increase
since 10/17/19
52-Week 46.10 +32.99% increase
on 01/28/19
Period Open:47.65
Price movement based on the high, low and last over the given period.
62.69 -2.20% decrease
on 01/15/20
+13.66 (+28.67%) increase
since 01/17/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies